scholarly journals Mucormycosis in Hematopoietic cell Transplant Recipients and in patients with Hematological Malignancies in the Era of New Antifungal Agents

2020 ◽  
Author(s):  
Matthew A Miller ◽  
Kyle C Molina ◽  
Jonathan A Gutman ◽  
Sias Scherger ◽  
Jessica M Lum ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Hematologic Malignancy ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Term Survival ◽  
Lower Treatment ◽  
All Cause Mortality

Abstract Objective The survival benefit of combination antifungal therapy for Invasive mucormycosis (IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT) is not well defined. Patients and Methods This multicenter, retrospective study included HM and HCT recipients with proven or probable IM between Jan 1, 2007-Dec 31, 2017 from ten transplant centers across North America. Results Sixty-four patients with proven (n = 47) or probable (n = 17) IM defined by 2008 EORTC/MSG consensus definitions were included. Thirty-nine (61%) were HCT recipients (95% allogeneic). Sites of infection included rhino-orbital-cerebral (33), pulmonary (30%), disseminated (19%), gastrointestinal (3%) and cutaneous (3%). Surgical debridement was performed in 66%. Initial antifungal treatment consisted of: AmB alone (44%), AmB + posaconazole (25%), AmB + echinocandin (13%), AmB + isavuconazole (8%), posaconazole alone (5%), and isavuconazole alone (3%). All-cause mortality at 30-days and 1-year were 38% and 66%, respectively. Initial treatment with AmB plus posaconazole or isavuconazole (n=28) was associated with a trend toward lower treatment failure compared to AmB (n=21) (42% vs. 64%, p=0.136) Conclusions Long-term survival with IM among HM and HCT populations remains poor. However, initial use of AmB + azole in conjunction with surgery may result in less treatment failure. More evidence from prospective controlled studies is needed to confirm this observation.

scholarly journals Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients

Blood ◽  
2015 ◽  
Vol 125 (11) ◽  
pp. 1724-1729 ◽  
Author(s):  
Alpana Waghmare ◽  
Steven A. Pergam ◽  
Keith R. Jerome ◽  
Janet A. Englund ◽  
Michael Boeckh ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Hematologic Malignancy ◽  
Hematopoietic Cell ◽  
Diagnostic Tools ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Diagnostic Assays ◽  
Key Points ◽  
Enterovirus D68

Key Points Enterovirus D68 can infect adult patients with hematologic malignancy and HCT recipients and lead to severe respiratory disease. Current diagnostic assays for enterovirus D68 are limited, and further studies on improved rapid diagnostic tools are needed.

scholarly journals ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

2010 ◽  
Vol 2 (2) ◽  
pp. e2010018 ◽  
Author(s):  
Maria L. Delioukina ◽  
Stephen J. Forman
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematologic Malignancy ◽  
Lymphocytic Leukemia ◽  
Hematopoietic Cell ◽  
New Drugs ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Purine Analogues

Chronic lymphocytic leukemia (CLL) is the most common hematologic malignancy in adults with an incidence rate of 4.2 per 100,000 per year. CLL frequently takes an indolent course, with some patients not requiring treatment for years, yet is incurable by currently available chemo- and immuno-therapeutic modalities. Despite high initial response rates, particularly to purine analogues, patients invariably relapse and subsequently develop resistance to therapy. The traditional “watchful waiting” approach to CLL is being challenged by data showing that treatments used early in the disease course impact long-term overall and progression-free survivals . The only curative treatment for CLL currently, is allogeneic hematopoeietic cell transplantation (alloHCT). In contrast to autologous transplant, myeloablative alloHCT for CLL patients generates durable remissions with promising survival plateaus; however, significant transplant related mortality (TRM) is also observed (25-50%) . At present the fact remains that for poor-risk CLL, alloHCT is the only treatment with the potential of providing long-term disease control. Future combinations with emerging low-toxicity therapies may further enhance the curative potential of allogeniec hematopoietic cell transplant. New drugs can also potentially enable refractory patients to attain response as a bridge to more effective stem cell transplantation.

scholarly journals Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates

2009 ◽  
Vol 15 (10) ◽  
pp. 1323-1330 ◽  
Author(s):  
Ian Nivison-Smith ◽  
Judy M. Simpson ◽  
Anthony J. Dodds ◽  
David D.F. Ma ◽  
Jeff Szer ◽  
...  
Keyword(s):  
General Population ◽  
Relative Survival ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant

scholarly journals Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients

2011 ◽  
Vol 87 (1) ◽  
pp. 123-125 ◽  
Author(s):  
Elliot Naidus ◽  
Lloyd Damon ◽  
Brian S. Schwartz ◽  
Cheryl Breed ◽  
Catherine Liu
Keyword(s):  
Hematologic Malignancy ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant

scholarly journals Penicillin Allergy Skin Testing as an Antibiotic Stewardship Intervention in Hematopoietic Cell Transplant Recipients

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S266-S267 ◽  
Author(s):  
Christopher Kovacs ◽  
Vasilios Athans ◽  
David Lang ◽  
Ronald Sobecks ◽  
Lisa Rybicki ◽  
...  
Keyword(s):  
Antibiotic Stewardship ◽  
Skin Testing ◽  
Hematopoietic Cell ◽  
Penicillin Allergy ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Allergy Skin Testing
Sign in / Sign up

Export Citation Format

Share Document